Wells Fargo & Company Allovir, Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALVR
# of Institutions
81Shares Held
49MCall Options Held
385KPut Options Held
2.3K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$8.36 Million0.24% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$4.88 Million0.27% of portfolio
-
Octagon Capital Advisors LP New York, NY4.2MShares$3.11 Million0.5% of portfolio
-
Black Rock Inc. New York, NY3.39MShares$2.51 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.94MShares$2.18 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $68.9M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...